Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire M Connell

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
ESMO Open|December 7, 2017
Activating HER2 mutations as emerging targets in multiple solid cancersClaire M Connell, Gary J Doherty
The Journal of Biological Chemistry|December 7, 2007
Nuclear survivin has reduced stability and is not cytoprotectiveClaire M Connell, Rita Colnaghi, Sally P Wheatley
Cancer Research|October 3, 2008
Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysisClaire M Connell, Sally P Wheatley, Iain A McNeish
The Journal of Biological Chemistry|September 5, 2006
Separating the anti-apoptotic and mitotic roles of survivinRita Colnaghi, Claire M Connell, Rachel M A Barrett, et al.
BMC Cancer|January 17, 2020
Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case reportClaire M Connell, Rebecca Brais, Hayley Whitaker, et al.
The Oncologist|October 13, 2017
Cancer Immunotherapy Trials Underutilize Immune Response MonitoringClaire M Connell, Sophie E M Raby, Ian Beh, et al.
Cell Metabolism|November 10, 2016
Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor ImmunityThomas R Flint, Tobias Janowitz, Claire M Connell, et al.
The Journal of Clinical Investigation|March 9, 2011
Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cellsClaire M Connell, Atsushi Shibata, Laura A Tookman, et al.
Molecular Cancer Research : MCR|October 11, 2015
RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian CancerLaura A Tookman, Ashley K Browne, Claire M Connell, et al.
Molecular Cancer|July 6, 2010
p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarkerMagdalena B Flak, Claire M Connell, Claude Chelala, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
ESMO Open|December 7, 2017
Activating HER2 mutations as emerging targets in multiple solid cancersClaire M Connell, Gary J Doherty
The Journal of Biological Chemistry|December 7, 2007
Nuclear survivin has reduced stability and is not cytoprotectiveClaire M Connell, Rita Colnaghi, Sally P Wheatley
Cancer Research|October 3, 2008
Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysisClaire M Connell, Sally P Wheatley, Iain A McNeish
The Journal of Biological Chemistry|September 5, 2006
Separating the anti-apoptotic and mitotic roles of survivinRita Colnaghi, Claire M Connell, Rachel M A Barrett, et al.
BMC Cancer|January 17, 2020
Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case reportClaire M Connell, Rebecca Brais, Hayley Whitaker, et al.
The Oncologist|October 13, 2017
Cancer Immunotherapy Trials Underutilize Immune Response MonitoringClaire M Connell, Sophie E M Raby, Ian Beh, et al.
Cell Metabolism|November 10, 2016
Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor ImmunityThomas R Flint, Tobias Janowitz, Claire M Connell, et al.
The Journal of Clinical Investigation|March 9, 2011
Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cellsClaire M Connell, Atsushi Shibata, Laura A Tookman, et al.
Molecular Cancer Research : MCR|October 11, 2015
RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian CancerLaura A Tookman, Ashley K Browne, Claire M Connell, et al.
Molecular Cancer|July 6, 2010
p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarkerMagdalena B Flak, Claire M Connell, Claude Chelala, et al.
Pageof 2